Tsumura & Co 2020 IR
The report highlights Tsumura's business model, which integrates Kampo medicine and Western medicine, and its strategic expansion in China. It outlines the company's progress under its third medium-term management plan, focusing on sustainable procurement of crude drugs and the establishment of a crude drug platform through the acquisition of China Medico Technology. The report also details Tsumura's efforts to establish scientific evidence for Kampo formulations and its commitment to environmental preservation, including upland cultivation of ginseng to prevent deforestation. Additionally, it presents key ESG data, showing progress in energy conservation, water recycling, and human resource development.
Company: Tsumura & Co
Sector: Health Care
Country: Japan
Year: 2020
Type: IR
Pages: 76
Tsumura & Co
Integrated Report
The report highlights Tsumura's business model, which integrates Kampo medicine and Western medicine, and its strategic expansion in China. It outlines the company's progress under its third medium-term management plan, focusing on sustainable procurement of crude drugs and the establishment of a crude drug platform through the acquisition of China Medico Technology. The report also details Tsumura's efforts to establish scientific evidence for Kampo formulations and its commitment to environmental preservation, including upland cultivation of ginseng to prevent deforestation. Additionally, it presents key ESG data, showing progress in energy conservation, water recycling, and human resource development.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2019
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women on Board
Women in Management
Employees